Investigating how certain immune cells help activate CD8 T cells against tumors
Understanding the Mechanisms of DC Licensing in CD8 T Cell Priming
This study is looking at how a special type of immune cell helps activate another important immune cell to better fight tumors and infections, and it's for anyone interested in understanding how our bodies can better recognize and attack cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11111301 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific type of immune cell, known as conventional dendritic cells (cDC1), activates CD8 T cells, which are crucial for fighting tumors and infections. The study examines the process of CD8 T cell priming, where cDC1 cells capture and present tumor-specific antigens to CD8 T cells, enabling them to recognize and attack cancer cells. The researchers aim to uncover the mechanisms behind 'DC licensing', a process that enhances the ability of cDC1 cells to fully activate CD8 T cells, which is essential for effective anti-tumor immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that may benefit from enhanced immune responses, particularly those involving CD8 T cell activation.
Not a fit: Patients with conditions unrelated to immune response or those who do not have tumors may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer immunotherapies by enhancing the activation of CD8 T cells against tumors.
How similar studies have performed: Previous research has shown promising results in enhancing immune responses through similar mechanisms, indicating potential for success in this area.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Murphy, Kenneth M — Washington University
- Study coordinator: Murphy, Kenneth M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.